Fotemustine
From Wikipedia, the free encyclopedia
|
Fotemustine
|
|
| Systematic (IUPAC) name | |
| diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate |
|
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C9H19ClN3O5P |
| Mol. mass | 315.691 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Fotemustine is a nitrosourea alkylating agent that is being investigated for use in the treatment of melanoma. A recent study (cited below) has shown that fotemustine produces better response rates and increased survival over dacarbazine, which is considered the "gold standard" for chemotherapy of melanoma.

